AN300112P
Recombinant MMP-2 Monoclonal Antibody
Größe
£361.80
War £402.00
- SKU:
- AN300112P
- Zusätzliche Namen:
- TBE,CLG,Matrix Metalloproteinase,MMP,CLG4,CLG4A,MMP-2,MMP-II,MONA,TBE-1,MMP2,72 kDa Gelatinase,72 kDa Type IV Collagenase,Gelatinase A,Matrix Metalloproteinase-2,72kD type IV collagenase,72kDa gelatinase,72kDa type IV collagenase),CLG 4,CLG 4A,Collagenase Type 4 alpha,Collagenase type IV A,Gelatinase alpha,Gelatinase neutrophil,Matrix metallopeptidase 2 gelatinase A 72kDa gelatinase 72kDa type IV collagenase,Matrix Metalloproteinase 2,Matrix metalloproteinase 2 (gelatinase A,Matrix
- Anwendung:
- WB
- Konzentration:
- 1 mg/ml
- Aufreinigung:
- Protein A Purified
- Lagerbedingungen:
- -20[o]C/-70[o]C Avoid freeze/thaw cycles., 2-8[o]C Avoid freeze/thaw cycles.
- Hersteller:
- Elabscience
- Host:
- Rabbit
- Reaktivitäten:
- Human
- Buffer:
- PBS
- Immunogen:
- Recombinant Human MMP-2 protein
- Klon:
- A1226
- Uniprot:
- P08253
- Synonyme:
- 72 kDa gelatinase;72 kDa type IV collagenase;CLG4;CLG4A;collagenase type IV-A;Gelatinase A;matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase);matrix metalloproteinase-2;matrix metalloproteinase-II;MMP-2;MMP-II;MONA;neutrophil gelatinase;TBE-1
- Weitere Details:
- Matrix Metalloproteinase-2 (MMP-2) is an enzyme that degrades components of the extracellular matrix and thus plays a pivotal role in cell migration during physiological and pathological processes. MMP-2 expression is dependent on extracellular matrix metalloproteinase inducer (EMMPRIN), Her2/neu, growth factors, cytokines, and hormones. Pro-MMP-2 activation needs MT1-MMP and TIMP-2 contribution. MMP-2 is changed in distribution and increased in amount in the ventral cochlear nucleus after unilateral cochlear ablation. A low level of MMP-2 is linked to a favorable prognosis in patients with a hormone receptor-negative tumor, usually associated with high risk. As a zymogen requiring proteolytic activation for catalytic activity, MMP-2 has been implicated broadly in the invasion and metastasis of many cancer model systems, including human breast cancer (HBC). Blocking MMP-2 secretion and activation during breast carcinoma development may decrease metastasis. The detection of active MMP-2 alone or the rate of pro-MMP-2 and active MMP-2 is considered a very sensitive indicator of cancer metastasis. Modulation of MMP-2 expression and activation through specific inhibitors and activators may thus provide a new mechanism for breast cancer treatment.
- Versandbedingungen:
- Blue Ice